<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168830</url>
  </required_header>
  <id_info>
    <org_study_id>C1007</org_study_id>
    <nct_id>NCT01168830</nct_id>
  </id_info>
  <brief_title>First in Man Trial - BIOSOLVE-I</brief_title>
  <acronym>BIOSOLVE-I</acronym>
  <official_title>BIOTRONIKS-Safety and Clinical Performance Of the First Drug-Eluting Generation Absorbable Metal Stent In Patients With de Novo Lesions in NatiVE Coronary Arteries (BIOSOLVE - I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in Man Trial with the drug eluting absorbable metal scaffold. To assess safety
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>de Novo Lesions in Native Coronary Arteries</condition>
  <arm_group>
    <arm_group_label>Investigational device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMS-3.0</intervention_name>
    <arm_group_label>Investigational device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt; 18 years and &lt; 80 years of age

          -  Written patient informed consent available prior to PCI

          -  Patients with stable or unstable angina pectoris or documented silent ischemia

          -  Patient eligible for PCI

          -  Patient acceptable candidate for coronary artery bypass surgery

        Exclusion Criteria:

          -  Left ventricular ejection fraction of &lt; 30%

          -  Presence of a visible thrombus in the target vessel visualized by angiography

          -  Lesion and/or way to lesion extremely calcified (e.g. IVUS catheter can not
             reach/cross the lesion)

          -  Patients with three-vessel where all three vessels require treatment

          -  Patients with previous CABG in the target vessel(s)

          -  Patients with known coronary artery spasm

          -  Myocardial infarction (STEMI/NSTEMI) within 4 weeks of the intended treatment.
             Determination of CKMB and/or troponin T or I is required.

          -  Patients with planned major surgery within 12 months after coronary intervention

          -  Patients with risk of either acetylsalicylic acid, clopidogrel or Prasugrel cessation

          -  Patients under current Phenprocoumon or Cumarine therapy

          -  Impaired renal function (serum creatinine &gt; 2.0mg/dl or 177micromol/l, determined
             within 72 hours prior to intervention)

          -  Additional coronary lesions (restenotic or de novo) in the same vessel which requires
             treatment

          -  Totally occluded coronary artery (TIMI flow 0)

          -  Lesions located within arterial or venous graft

          -  Ostial lesions

          -  Previous and/or planned brachytherapy of target vessel

          -  Target lesion located in left main coronary artery

          -  Stroke or TIA &lt; 6 months prior to procedure

          -  Patient with signs of a cardiogenic shock

          -  Surgeries of any kind within 30 days prior to screening

          -  Patient with bleeding diathesis in whom anticoagulation or antiplatelet medication is
             contraindicated

          -  Pregnant and/or breast-feeding females or females who intend to become pregnant

          -  Patient currently enrolled in other investigational device or drug trial

          -  Patient with expected incompliance to medical (antiplatelet, anticoagulation) therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Middelheim Hospital</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Essen, Westdeutsches Herzzentrum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

